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Introduction  
 
The therapeutic potential of many active 
substances cannot be realized in clinical practice due 
to adverse physic–chemical properties, variable 
pharmacokinetics and a range of adverse effects 
causing low bioavailability and unsatisfactory 
therapeutic concentration in the target tissue. In 
order to overcome these problems, in recent years 
the emphasis has been placed on the study and 
characterization of different types of nanoparticles 
that offer many advantages over conventional 
therapy. The most common investigated and 
characterized nanosystems are dendrimers, as a new 
class of polymers.  
Dendrimers as nanosystems are formulated from 
materials that are biocompatible, biodegradable and 
non-immunogenic. They have unique properties like 
thermodynamic stability, small particle size (1-20 
nm), low polydispersity index and negative zeta 
potential (Svanson et al., 2018). The dendrimer 
structure is compatible with a range of hydrophilic 
and hydrophobic active substances with high 
encapsulation efficiency using different preparation 
methods (Abasi et al., 2014).  
There are a several types of used dendrimers but 
PAMAM dendrimers are the most commonly 
studied dendrimers due to documented safety 
studies, and are candidates for encapsulating a large 
number of antineoplastic agents (Dubey et al., 2019).  
The therapeutic efficacy of many antineoplastics 
is limited due to their poor penetration into tumor 
tissue and serious adverse effects on healthy cells. 
This section discusses the results of clinical trials 
incorporating the most commonly used 
antineoplastic drugs in dendrimer formulations 
(Mariyam et al., 2018). 
 
Materials and methods  
 
The propose of this paper is to review the 
structure of the dendrimers and the role of the 
components in their structure as well as compare and 
detect the factors which affect the stability of 
dendrimers and developing different formulation 
methods.  We did a research for characterization of 
dendrimers with encapsulated active substance and 
processing and comparison of clinical trial results on 
the efficacy and toxicity of drugs incorporated into 
dendrimers against different types of disease.  
Our research is made for characterization of 
incorporating the most commonly used 
antineoplastics drugs (doxorubicin, paclitaxel and 
docetaxel, camptothecin) in dendrimer formulations. 
To accomplish these goals, we used data from 
relevant literature sources from primary, secondary 
and tertiary literature, with emphasis on original 
scientific research on the characterization and 
evaluation of dendrimers with incorporated active 
substances and processing of their results. We 
systematized the summarized literary data according 
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to the actual treatment of the problem, noted the 
formulation aspects of using different methods and 
active substances, and identified the advantages and 
disadvantages by highlighting the possibilities of 
optimizing the therapy of various diseases of the 
dendrimer. We discussed the processed results, 
tabulated the patented products, and drew 
appropriate conclusions from the evaluated results. 
 
Results and discussion  
 
Doxorubicin is used in the treatment of several 
types of cancers, but due to the adverse effects, 
several formulations of doxorubicin with dendrimers 
have been investigated, and the results have shown 
that P1 and P2 particles inhibit cancer growth twice 
as much, and that is result of the additive effect of 
complex of dendrimers with DOX, as well as a 
significant reduction in side effects (Zhang et al., 
2018).  
PAMAM dendrimers have been proven to be 
ideal platforms for delivering also paclitaxel and 
docetaxel, significantly increasing water solubility 
and providing higher bioavailability (Li et al., 2018). 
Encapsulation of camptothecin resulted in a 
significantly higher percentage of accumulation in 
malignant cells compared to the free drug 
(Thiagarajan et al., 2010). 
In addition to the widespread use of 
antineoplastic delivery, numerous clinical studies 
have shown that dendrimers, especially third- and 
fifth-generation PAMAM, are promising candidates 
for transdermal, oral and ocular delivery of 
numerous active substances with adverse 
pharmacokinetic properties. It is possible to modify 
the membrane with specific ligands that will provide 
targeted delivery to certain tumor cells with 
overexpressing receptors that will allow controlled 
release of the active substance into the malignant 
cell without affecting the surrounding tissues 
(Wolinsky et al., 2018). 
 
Conclusion 
 
Dendrimers are a challenge in modern therapy 
given the fact that they provide targeted delivery of 
drugs that can increase the bioavailability of the 
encapsulated drug and enable controlled and 
prolonged therapeutic activity.  
 
 
 
The high cost, low solubility, volatility at certain 
pH values and short half-life make the application of 
other nanoparticles significantly difficult. 
Dendrimers provide controlled delivery of different 
types of active substances followed by increased 
therapeutic effect, achieving high concentration in 
the target cell and reducing the adverse effects 
From the processed data, we concluded that 
dendrimers are optimal carriers for many active 
substances providing higher solubility, greater 
stability and improved bioavailability, especially at 
antineoplastic treatment. 
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